119th Congress · introduced in the Senate · Apr 30, 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Official title from Congress.gov
Latest action (Aug 10, 2026): Held at the desk.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Reported to Senate (Jul 16, 2026)
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
• grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
• grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
• a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Show the full summary (3 more paragraphs)Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Held at the desk.
Received in the House.
Message on Senate action sent to the House.
Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
Department of Health and Human Services · Drug therapy · Food and Drug Administration (FDA) · Government information and archives · Health programs administration and funding · Internet, web applications, social media · Medical research · National Institutes of Health (NIH) · Neurological disorders · Public-private cooperation · Research administration and funding
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
4 citations.
THE ALS ASSOCIATION · lobbying firm or registrant: THE ALS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - P…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
I AM ALS · lobbying firm or registrant: I AM ALS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$40,000
Spent on own lobbying
(H.R.8205 / S.4472) Reauthorization and fully funding of the ACT for ALS (Public Law 117-79) for continued access to promising treatments and research. (S.925/H.R.2036) Credit fo…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE ALS ASSOCIATION · lobbying firm or registrant: THE ALS ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - P…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
I AM ALS · lobbying firm or registrant: I AM ALS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 13, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
(H.R.8205 / S.4472) Reauthorization and fully funding of the ACT for ALS (Public Law 117-79) for continued access to promising treatments and research. (S.925/H.R.2036) Credit fo…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing